Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Chattem Dexatrim Results To Reduce Weight-Loss Side Effects, Firm Says

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Dexatrim Results, in regular and ephedrine-free formulas, will be the only weight-loss products on the mass market featuring an antioxidant complex designed to minimize side effects normally caused by diet pills, Chattem said Sept. 20.

You may also be interested in...



Chattem pHisoderm Clear Swab Launch Will Target “Back-To-School” Crowd

Chattem will back the launch of pHisoderm Clear Swab with dedicated ads and product sampling

Chattem pHisoderm Clear Swab Launch Will Target “Back-To-School” Crowd

Chattem will back the launch of pHisoderm Clear Swab with dedicated ads and product sampling

Chattem pHisoderm Clear Swab Launch Will Target “Back-To-School” Crowd

Chattem will back the launch of pHisoderm Clear Swab with dedicated ads and product sampling

Table

View full table

Related Content

HBW Insight

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS093051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By